Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 13/20 | 0.61 |
| ▸ | PPARA | Q07869 | 11/20 | 0.61 |
| ▸ | SRR | Q9GZT4 | 2/20 | 0.54 |
| ▸ | PSAT1 | Q9Y617 | 2/20 | 0.54 |
| ▸ | PPARD | Q03181 | 2/20 | 0.48 |
| ▸ | MME | P08473 | 1/20 | 0.46 |
| ▸ | ACE | P12821 | 1/20 | 0.46 |
| ▸ | CPA1 | P15085 | 1/20 | 0.46 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2384187 | 0.90 | SLC1A3 (0.53) | PPARGPPARASRRPPARD | |
| SCHEMBL15528161 | 0.90 | SLC1A3 (0.53) | PPARGPPARASRRPPARD | |
| SCHEMBL1273202 | 0.90 | SLC1A3 (0.53) | PPARGPPARASRRPPARD | |
| SCHEMBL11500191 | 0.88 | PPARA (0.79) | PPARGPPARA | |
| SCHEMBL5870279 | 0.84 | PPARG (0.55) | PPARGPPARASRRPSAT1PPARD | |
| SCHEMBL2215263 | 0.82 | PPARA (0.51) | PPARGPPARAPPARDMME | |
| SCHEMBL31513588 | 0.81 | LDHA (0.56) | PPARGPPARAPPARD | |
| SCHEMBL21121968 | 0.81 | LDHA (0.56) | PPARGPPARAPPARD | |
| SCHEMBL3260466 | 0.80 | GAA (0.57) | PPARGPPARASRRPSAT1MME | |
| SCHEMBL1973572 | 0.80 | GAA (0.57) | PPARGPPARASRRPSAT1MME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110178042-A1 | Hydroxamic Acid Derivatives Useful as Antibacterial Agents | PFIZER INC. (US) | 2011-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178042-A1 | Hydroxamic Acid Derivatives Useful as Antibacterial Agents | HCAR1, HDAC1, H1-0 | PPARG 1181/4885PPARA 1586/4885SRR 333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.